INTRODUCTION
============

The neutrophil-to-lymphocyte ratio has been recently emerged as a new marker of inflammation and was found to be associated with the severity and prognosis of several respiratory and cardiac diseases ([@B1]--[@B4]). Sarcoidosis is a systemic inflammatory disease characterized by formation of granulomas in different affected organs ([@B5],[@B6]). Pulmonary hypertension is a feared complication in patients with sarcoidosis as it is an important negative prognostic factor, which is reflected in the added priority given to these subjects for orthotopic lung transplantation ([@B7],[@B8]). Pulmonary hypertension is considered a vasculopathy caused by excessive vascular cell growth with inflammation playing a major role ([@B8]). Previous studies showed that NLR was significantly elevated in PH patients compared with healthy volunteers ([@B9]) and may be useful for the assessment of disease severity ([@B10]). The increased prevalence of PH in systemic inflammatory diseases such as sarcoidosis is well known ([@B7],[@B8]). Although the gold standard in diagnosing PH is the direct measurement of the pulmonary artery pressure with right heart catheterization (RHC), RHC needs highly skilled personnel and advanced technology that are not available in many settings with limited resources ([@B11]). Instead, echocardiography is widely used to estimate pulmonary artery systolic pressure ([@B12]). Echocardiography is not a simple and easy tool to be considered as a point-of-care test in primary care setting. We hypothesized that the degree of systemic inflammation (as measured by NLR) would be significantly higher in sarcoidosis subjects with PH compared to those without PH and could be an appropriate test for primary care setting. Herein, we aimed to assess the relationship between NLR and PH in sarcoidosis patients.

MATERIALS AND METHODS
=====================

An IRB-approved retrospective chart review (approval number 20130195001) was conducted at University of Illinois in Chicago from January 2010 through January 2015 on adult patients diagnosed with sarcoidosis. Cases were divided into two groups based on presence or absence of PH, which was diagnosed when the pulmonary artery systolic pressure was \>25 mmHg using transthoracic echocardiogram. Patients with left ventricular systolic dysfunction (EF≤40 mmHg) were excluded. In subjects with more than one complete blood count during hospitalization, the average of the highest and lowest absolute neutrophil and lymphocyte counts was used.

Continuous variables were compared using Student t-test and categorical variables were compared using the Chi-square test. To determine the ideal cutoff value of NLR, receiver operating characteristic (ROC) curve was used. To assess whether NLR was independently associated with PH in sarcoidosis patients, multivariate regression analysis with backward stepwise elimination was performed.

RESULTS
=======

A total of 107 cases diagnosed with sarcoidosis were included in the study, among which 28 patients (26%) had PH. The mean age of the study population was 53.4±9.4 years; 76.9% were females, 70% were African Americans and the average duration of sarcoidosis was 12 years.

Characteristics of sarcoidosis patients with and without PH are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Baseline demographic, clinical and laboratory characteristics among sarcoidosis cases with and without pulmonary hypertension

                                             **All (n=107)**   **Sarcoidosis with PHTN (n=28)**   **Sarcoidosis without PHTN (n=79)**   **P value**
  ------------------------------------------ ----------------- ---------------------------------- ------------------------------------- -------------
  Age (mean ± SD)                            53.4 ± 9.4        57.1 ± 8.8                         51.9 ± 9.3                            0.011
  Female sex % (n)                           76.6% (82)        82.1% (23)                         74.7% (59)                            0.425
  BMI (mean ±SD)                             31.9 ± 8          32.2 ± 7.2                         31.9 ± 8.3                            0.836
  Duration of sarcoidosis (y, mean± SD)      12.2 ± 9.1        14.3 ± 10.7                        11.5 ± 8.5                            0.18
  African American % (n)                     70.1% (75)        82.1% (23)                         65.8% (52)                            0.112
  Diabetes % (n)                             31.4% (33)        17.9% (5)                          36.4% (28)                            0.077
  Dyslipidemia % (n)                         24.5% (26)        25% (7)                            24.4% (19)                            0.946
  CKD % (n)                                  3.7% (4)          3.6% (1)                           3.8% (3)                              0.957
  PCI or CABG % (n)                          1.9% (2)          0% (0)                             2.5% (2)                              0.543
  Atrial fibrillation % (n)                  5.6% (6)          10.7% (3)                          3.8% (3)                              0.190
  Pulmonary sarcoidosis % (n)                91.9% (91)        96.3% (26)                         90.3% (65)                            0.347
  Extrapulmonary sarcoidosis % (n)           64.5% (69)        60.7% (17)                         65.8% (52)                            0.628
  Rheumatoid arthritis % (n)                 3.7% (4)          0% (0)                             5.1% (4)                              0.291
  Asthma % (n)                               26.4% (28)        28.6% (8)                          25.6% (20)                            0.763
  OSA % (n)                                  24.5% (26)        29.6% (8)                          22.8% (18)                            0.477
  Bronchiectasis % (n)                       9.3% (10)         21.4% (6)                          5.1% (4)                              0.018
  FVC % (mean ±SD)                           93.2 ±20.9        84.1 ± 24.8                        96.4 ± 18.4                           0.014
  FEV1 % (mean ±SD)                          88 ± 24.9         74.5 ± 27.9                        92.8 ± 22                             0.002
  TLC % (mean ±SD)                           89.1 ±15.6        84.7 ± 16.8                        90.7 ± 15                             0.114
  RV % (mean ±SD)                            99.4 ±26.7        102.2 ± 29.8                       98.3 ± 25.7                           0.605
  FRC % (mean ±SD)                           97.4 ±22.1        102.5 ± 20.2                       95.6 ± 22.7                           0.291
  DLCO % (mean ±SD)                          67 ± 20.3         60.8 ± 18.2                        69.3 ± 20.7                           0.088
  PASP (mmHg, mean ±SD)                      35.1 ±17.4        41.1 ± 17.7                        21.2 ± 2.3                            0.000
  EF (mean ±SD)                              57.8 ± 4.8        57.5 ± 5                           58 ± 4.7                              0.672
  Neutrophil (mean ±SD)                      4.9 ± 2           5.5 ± 2.4                          4.7 ± 1.8                             0.098
  Lymphocyte (mean ±SD)                      1.76 ± 0.7        1.6 ± 0.6                          1.8 ± 0.8                             0.221
  Neutrophil/Lymphocyte ratio (mean± SD)     3.4 ± 2.5         4.1 ± 2.9                          3.2 ± 2.4                             0.120
  Neutrophil/Lymphocyte ratio \> 3.5 % (n)   30.7% (31)        50% (13)                           24% (18)                              0.016
  CRP (mean ±SD)                             2.5 ± 4.2         3 ± 4.1                            2.4 ± 4.2                             0.562
  ESR (mean ±SD)                             35.2 ±33.4        45.8 ± 32.6                        32.6 ± 33.3                           0.160
  Oral steroid % (n)                         83.3% (85)        88.9% (24)                         81.3% (61)                            0.372
  DMARD % (n)                                44.3% (47)        32.1% (9)                          48.7% (38)                            0.133
  Methotrexate % (n)                         29.9% (32)        17.9% (5)                          34.2% (27)                            0.112
  Azathioprine% (n)                          4.7%(5)           7.1% (2)                           3.8%(3)                               0.478
  Sildenafil% (n)                            7.5%(8)           14.3% (4)                          5.1% (4)                              0.126
  Warfarin% (n)                              2.8%(3)           7.1% (2)                           1.3% (1)                              0.150

PHTN: Pulmonary hypertension, BMI: Body mass index, CKD: Chronic kidney disease, PCI: Percutaneous coronary intervention, CABG: Coronary artery bypass graft, OSA: Obstructive sleep apnea, PASP: Pulmonary artery systolic pressure, EF: Ejection fraction, ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, DMARD: Disease modifying anti-rheumatic drug, y: Year, m: Mean, SD: Standard deviation.

Compared to sarcoidosis patients without PH, those with PH were significantly older (57.1±8.8 vs. 51.9±9.3 years, P=0.011), had a higher frequency of bronchiectasis (21.4% vs. 5.1%, P=0.012), lower FVC% (84.1±24.8% vs. 96.4±18.4%, P=0.014), lower FEV1% (74.5±27.9% vs. 92.8±22%, P=0.002) and a trend towards lower DLCO% (60.8±18.2% vs. 69.3±20.7%, P=0.088). Also, sarcoidosis patients with PH had a trend towards higher neutrophil count (5.5±2.4 vs. 4.7±1.8, P=0.098), lower lymphocyte count (1.6±0.6 vs. 1.8±0.8, P=0.221) and higher NLR (4.1±2.9 vs. 3.2±2.4, P=0.120). A NLR \> 3.5 occurred with significantly higher frequency in sarcoidosis patients with PH (50% vs. 24%, P=0.016). The value of 3.5 was determined as the most appropriate cutoff value for NLR for distinction between sarcoidosis patients with and without PH, which yielded a sensitivity of 50%, specificity of 78%, PPV of 41.9% and NPV of 81.4% with an area under curve of 0.619. In the multivariate model, NLR \>3.5 remained independently associated with PH (OR 3.254, 95% CI 1.094--9.678, P=0.034). We found no significant association between PH and CRP or ESR. [Figure 1](#F1){ref-type="fig"} is a forest plot of the variables used in the multivariate model.
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DISCUSSION
==========

In this retrospective study, we were able to show an independent relationship between NLR, a marker of inflammation, and PH in sarcoidosis patients. It is obvious that patients with a systemic inflammatory disease such as sarcoidosis will have an elevated NLR, and this was in fact demonstrated by Iliaz and colleagues who found a NLR of 2.48±1.1 in sarcoidosis patients compared with 1.73±0.7 in the control group (P\<0.001)([@B13]). Nonetheless, as we speculated, a higher NLR (\>3.5) in sarcoidosis patients signifies a more intense inflammatory response, which may be the underlying subset and pathophysiological basis for development of PH. These results raise hope and provoke further research to study the utility of this promising marker in sarcoidosis-associated PH. This test is a good negative test owing to the relatively good specificity (78%) and NPV (81.4%). Compared to other inflammatory markers, the NLR is a simple, inexpensive and widely available test that is routinely measured in office-based settings and adds no extra cost. Our study limitations included the single center retrospective design and the relatively small cohort due to rarity of the disease.

We conclude that level of inflammation in sarcoidosis patients may be associated with development of PH. Also, NLR has low sensitivity and PPV for diagnosis of PH in sarcoidosis patients and therefore it is not an ideal screening tool. However, its high NPV makes it an interesting tool to exclude PH in patients with sarcoidosis. Larger studies are required to evaluate the value of NLR in predicting sarcoidosis-associated PH and confirm our findings before being used in the primary care setting.
